2021
DOI: 10.1016/j.metop.2021.100141
|View full text |Cite
|
Sign up to set email alerts
|

Herbal medicine use for the management of COVID-19: A review article

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
48
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 85 publications
(56 citation statements)
references
References 61 publications
1
48
0
Order By: Relevance
“…Traditional Chinese medicine (TCM) showed appreciable results in improving clinical symptoms and reducing mortality and recurrence rates of the virus [ 9 ]. A traditional Chinese medicine formula, Taiwan ChingguanYihau (NRICM101), has been administered to patients with COVID-19 in Taiwan since April 2020.…”
Section: Introductionmentioning
confidence: 99%
“…Traditional Chinese medicine (TCM) showed appreciable results in improving clinical symptoms and reducing mortality and recurrence rates of the virus [ 9 ]. A traditional Chinese medicine formula, Taiwan ChingguanYihau (NRICM101), has been administered to patients with COVID-19 in Taiwan since April 2020.…”
Section: Introductionmentioning
confidence: 99%
“…We believe this is one of the first published studies to develop a method (an instrument) that can help community pharmacists identify falsified and substandard herbal supplements within their pharmacies Supplementary Appendix 1. This is important given the anticipated growth in sales of herbal supplements driven by a likely increase in the number of patients seeking herbal supplements from community pharmacies in the future, exacerbated by the current COVID-19 pandemic with patients seeking herbal medicines in the absence of proven effective pharmaceuticals assisted by studies demonstrating their benefits ( Alsayari et al, 2018 ; Mirzaie et al, 2020 ; Silveira et al, 2020 ; Brendler et al, 2021 ; Feng et al, 2021 ; Khanna et al, 2021 ; Market Data Forecast, 2021 ; Demeke et al, 2021 ; Sefah et al, 2021a , 2021b ). In addition, growing reports of falsified or adulterated herbal supplements, with concerns for the health of patients ( BottomLineInc, 2014 ; Newsmax Fake, 2015 ; Raclariu et al, 2017 ; Kum et al, 2021 ).…”
Section: Discussionmentioning
confidence: 99%
“…The use of corticosteroids is still debated, and current World Health Organization guidelines advise against using them unless there is some concurrent indication, such as chronic obstructive pulmonary disease exacerbation or pressor-refractory shock ( 156 ). Some of the drawbacks of medicinal plants include a lack of information on the safety profile and dosage for various ailments ( 155 ). There are still no well-designed PK and pharmacokinetic-pharmacodynamic (PK-PD) data of COVID-19 patients available, as well as no high-quality evidence to support the use of the above repurposed medications for COVID-19 treatment.…”
Section: Limitation Of Drugs That Used To Treat the Covid-19 Infectionmentioning
confidence: 99%
“…As a result, various pharmacological classes are being repurposed, including antivirals (like indinavir, ritonavir, saquinavir, darunavir, lopinavir, favipiravir, remdesivir, galidesivir, emtricitabin, tenofovir, oseltamivir, penciclovir, ganciclovir, ribavirin, umifenovir etc. ), immunomodulators (like tocilizumab and interferon), enzyme inhibitors (like nafamostat, camostat and carfilzomib), antimalarial (like chloroquine and hydroxychloroquine), antiparasitic (ivermectin), anthelmintics (niclosamide), antibiotics (like teicoplanin, azithromycin,eravacycline, valrubicin, streptomycin, nitazoxanide, caspofungin, and colistin), antirheumatoid (like baricitinib), corticosteroids and herbal medicines (151)(152)(153)(154)(155). There are also several obstacles to overcome in terms of dose adjustments, acute/chronic toxicity, and unfavorable in vivo pharmacokinetic (PK) properties (e.g.…”
Section: Limitation Of Drugs That Used To Treat the Covid-19 Infectionmentioning
confidence: 99%